InsidersTradesSigma
Niagen Bioscience, Inc. Stock: price and insider trades · United States · SEC (Form 4)
Track the Niagen Bioscience, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Niagen Bioscience, Inc. has published 6 reports. Market capitalisation: €278.8m. The latest transaction was reported on 8 July 2026 (Attribution). Among the most active insiders: Fried Robert N. All data is openly available.
6
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Niagen Bioscience, Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$12.60.
29Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 3,597 of 25,829 companies
70.6
score / 100
Value56
Quality85
FCF yld4.9%
Earn yld6.5%
EV/EBITDA17.2x
ROE27%
Gross mgn64%
Net mgn13%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 8 July 2026
Declarations6 total
1,106 shares@ US$2.71Common StockSEC:0001417952-26-000002:0
2,314 shares@ US$2.71Common StockSEC:0002042509-26-000001:0
4,255 shares@ US$2.71Common StockSEC:0001834681-26-000001:0
20,000 shares@ US$2.610.0088% mcap50.0% of flowCommon StockSEC:0001417952-26-000001
20,000 shares@ US$2.610.0088% mcap50.0% of flowCommon StockSEC:0001417952-26-000001:0
66,667 shares@ US$3.3069.2% of flowCommon StockSEC:0001628280-25-017223:0
6 of 6 declarations
About Niagen Bioscience, Inc.
Niagen Bioscience, Inc. (NASDAQ: NAGE) is a U.S.-based biosciences company headquartered in Los Angeles, California, United States. The company originated as ChromaDex and adopted its current name on March 19, 2025, reflecting a strategic shift toward NAD+ science and healthy aging. Its business has been built around Niagen®, a patented form of nicotinamide riboside (NR), a precursor to NAD+ that the company positions as a scientifically validated ingredient for cellular metabolism and longevity-related applications. Niagen Bioscience now presents itself as a science-led company combining intellectual property, research collaborations, and commercialization of evidence-based products. ([investors.niagenbioscience.com](https://investors.niagenbioscience.com/news/news-details/2025/ChromaDex-Evolves-Into-Niagen-Bioscience-Marking-a-New-Era-of-Uncovering-the-Potential-of-NAD-With-Precision-Science/default.aspx?utm_source=openai)) The company’s model is organized around three main activities. First is consumer health, led by Tru Niagen®, its flagship oral supplement brand. Second is the ingredients segment, which supplies food-grade and pharmaceutical-grade Niagen® to third-party manufacturers and, in the pharmaceutical channel, to authorized 503B outsourcing facilities. Third is the analytical reference standards and services business, a legacy activity that the company is now strategically exiting through the announced sale of substantially all of those assets. This divestiture underscores a clear focus on NAD+ science, IP monetization, and commercial growth in the longevity sector. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001386570/000138657026000013/cdxc-20251231.htm?utm_source=openai)) From a competitive standpoint, Niagen Bioscience differentiates itself through a science-heavy brand, a broad patent portfolio around NR, and an extensive global research network. The company describes Tru Niagen as the leading NAD+ boosting oral supplement in the United States based on revenue data from the major U.S. e-commerce marketplace for the referenced period. It also aims to deepen its platform through higher-value formats such as Niagen IV and injectable products, which broadens the commercial opportunity beyond the core supplement business. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1386570/000138657025000015/pressreleasedatedoctober62.htm?utm_source=openai)) Recent news has emphasized both product expansion and scientific validation. Niagen Bioscience launched Tru Niagen Beauty and, in 2026, introduced a Niagen Skincare Innovation Lab and the limited-release Niagen NanoCloud™ topical product, extending the Niagen ingredient story into skincare. The company has also highlighted clinical and research milestones in long COVID, Parkinson’s disease, and external research agreements, reinforcing its positioning as a platform that converts scientific credibility into commercial optionality. Geographically, the group operates from the United States but has an international footprint through research partnerships, product distribution, and global collaborations. For investors, the stock combines consumer health exposure, a healthy-aging thesis, and a NASDAQ-listed scientific growth story. ([investors.niagenbioscience.com](https://investors.niagenbioscience.com/news/news-details/2026/Niagen-Bioscience-Launches-Niagen-Skincare-Innovation-Lab-and-Debuts-Dermatologist-Tested-Niagen-NanoCloud-From-Tru-Niagen-Powered-by-Patented-Niagen/default.aspx?utm_source=openai))
